Intrinsiqq
NovaBridge Biosciences American logo

NovaBridge Biosciences American Insider Trading

NBP

Compare
Last 12 months

Insiders bought 663K and sold 154K on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. Chief Bus. Development Officer Sean Wuxiong Cao sold 80K on Sep 9, 29% of their stake, outside a plan.

Net open-market
+509K
2 buys · 7 sales
Under a 10b5-1 plan
0%
of the value sold
Insiders who bought / sold
1 / 3
executives and directors
Last open-market buy
Nov 2026
Nov 18, 2026

Get an email when NBP's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

  • Nov 17 – 18
    Mark Arnold Hagler
    Chief Commercial Officer · bought 230,000 at avg $0.37
    86K
    100% of stake
  • Sep 18No plan
    Phillip Andrew Dennis
    Chief Medical Officer · sold 8,209 at $0.71
    6K
    4.5% of stake
  • Sep 9No plan
    Sean Wuxiong Cao
    Chief Bus. Development Officer · sold 107,978 at $0.74
    80K
    29% of stake
  • Aug 31No plan
    Cong Claire Xu
    EVP, Clinical Development · sold 3,282 at $0.79
    3K
    1.1% of stake
  • Jul 6No plan
    Cong Claire Xu
    SVP, Clinical Development · sold 4,485 at $0.89
    4K
    1.5% of stake
  • Jun 18No plan
    Phillip Andrew Dennis
    Chief Medical Officer · sold 8,494 at $0.66
    6K
    5.1% of stake
  • Jun 1No plan
    Cong Claire Xu
    SVP, Clinical Development · sold 3,494 at $3.94
    14K
    1.2% of stake
  • May 14No plan
    Sean Wuxiong Cao
    See Remarks · sold 21,399 at $1.99
    43K
    38% of stake
  • Apr 24
    Mark Arnold Hagler
    See Remarks · bought 230,000 at $2.51
    577K
    New position
How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch NBP, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biotechnology · Pick stocks to compare with NBP

CompareIntrinsic value
NEWBRY.XSTONewbury Pharmaceuticals AB
€0.11+0.91%40
HPHA.XETRHeidelberg Pharma AG
€2.01-2.90%10
MEDCL.XPARMedincell SA
€26.70-2.05%40
ZTEKZentek Ltd.
€0.33-0.60%40
XTXXFAdastra Holdings Ltd.
€0.08+0.00%40
XRTXXORTX Therapeutics Inc.
$0.84-5.73%10
VALNValneva SE Sponsored ADR
$5.16-3.82%0
TRIBTrinity Biotech plc Sponsored ADR
$6.24+13.66%10

Held by ETFs

NBP is in 4 US ETFs. The largest of them, with NBP's weight in each:

Spot a number that looks wrong?

Download this analysis as a PDF (Pro)

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing NBP

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.